Borderline Resectable Pancreatic Adenocarcinoma

Neoadjuvant therapy refers to treatment aimed at shrinking a tumour before the main treatment, which is usually surgery, is given.

Neoadjuvant therapy can be considered in patients with a subtype of pancreatic adenocarcinoma described as borderline resectable. Borderline resectability implies that there is uncertainty whether a tumour can be removed completely by surgery.

There is insufficient evidence to recommend a specific treatment. Subsequent chemoradiation can be considered after initial chemotherapy.

If available, it is recommended for the patient to participate in clinical trials.